Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03711578
Title Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rhizen Pharmaceuticals SA
Age Groups: adult | senior
Covered Countries USA | AUS

No variant requirements are available.